Geminor M 3 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The extended-release formulation of Geminor M 3 Forte ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. This combination is indicated for patients inadequately controlled on diet and exercise alone or those not responding sufficiently to monotherapy with either agent. Geminor M 3 Forte aids in reducing fasting and postprandial blood glucose levels, contributing to improved HbA1c values. It is essential to monitor renal function before and during therapy due to the risk of lactic acidosis associated with metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia related to glimepiride. This medication should be used under medical supervision with appropriate lifestyle modifications to achieve optimal glycemic control.